Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Oncotarget ; 8(28): 46593-46600, 2017 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-28423741

RESUMO

The immunomodulatory drug lenalidomide is highly effective against newly diagnosed and relapsed/refractory multiple myeloma (MM), but serious and even fatal infections have been associated with its use. In this meta-analysis, we assessed the overall risk of infection to MM patients treated with lenalidomide. Eleven phase II or III clinical trials, comprising 3,210 subjects, were selected from the Embase, Pubmed, and Cochrane Library databases, from the Clinical Trial Registration website, and from meeting abstracts and virtual presentations at the American Society of Clinical Oncology. Main outcome measures were overall incidence, relative risk (RR), and 95% confidence intervals (CIs) of reported infection events. Fixed-effect or random-effect models were used in the statistical analyses, depending on the between-study heterogeneity. The overall incidence of high-grade infection was 14.32% (95% CI: 12.08%-16.90%) and high-grade infection's pooled RR was 2.23 (95% CI: 1.71-2.91, P < 0.0001) for all 11 studies evaluated. No evidence of publication bias for the incidence of high-grade infection was detected using Begg's funnel plot and Egger's test (P = 0.2; 95% CI: -1.70, 1.23). From this meta-analysis, it appears lenalidomide use is associated with an increased risk of high-grade infection. Moreover, fatal infection events occurred only in patients treated with lenalidomide; no infection-related deaths were observed among controls. These data indicate that accurate diagnosis and optimal management of infection in MM patients treated with lenalidomide could be critical for treatment efficacy.


Assuntos
Antineoplásicos/efeitos adversos , Fatores Imunológicos/efeitos adversos , Infecções/epidemiologia , Infecções/etiologia , Mieloma Múltiplo/complicações , Talidomida/análogos & derivados , Antineoplásicos/uso terapêutico , Humanos , Fatores Imunológicos/uso terapêutico , Incidência , Infecções/diagnóstico , Infecções/mortalidade , Lenalidomida , Mortalidade , Mieloma Múltiplo/tratamento farmacológico , Viés de Publicação , Risco , Índice de Gravidade de Doença , Talidomida/efeitos adversos , Talidomida/uso terapêutico
2.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-315364

RESUMO

<p><b>OBJECTIVE</b>To develop an HPLC method for simultaneous determination of three major sesquiterpene lactones in Radix Linderae.</p><p><b>METHOD</b>The chromatographic separation was achieved on a Diamonsil C18 column (4.6 mm x 250 mm, 5 microm) using isocratic elution of acetonitrile-water (containing 0.1% H3 PO4) (45 : 55) at a flow rate of 1.0 mL x min(-1). Detection was carried out using a photodiode array detector at 220 nm.</p><p><b>RESULT</b>The calibration curves were linear in the range of 0.001 8-0.036 0 g x L(-1) for hydroxylinderstrenolide (R2 = 0.999 8), 0.016 2-0.323 2 g x L(-1) for neolinderalactone (R2 = 0.999 9), 0.010 5-0.209 9 g x L(-1) for linderane (R2 = 0.999 9), respectively. The average recoveries were 100.0% for hydroxylinderstrenolide, 98.8% for neolinderalactone and 98.9% for linderane with RSD not more than 3.3%.</p><p><b>CONCLUSION</b>The established method was proved to be simple, sensitive and credible, and can be applied to quality control of Radix Linderae.</p>


Assuntos
Cromatografia Líquida de Alta Pressão , Métodos , Medicamentos de Ervas Chinesas , Lactonas , Lindera , Química , Sesquiterpenos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...